The DOI matches its Crossref record; 169 of the 172 references it cites were found in a registry or an index.
A PDK-1 allosteric agonist neutralizes insulin signaling derangements and beta-amyloid toxicity in neuronal cells and in vitro
Open accessAbstract
The Alzheimer’s brain is affected by multiple pathophysiological processes, which include a unique, organ-specific form of insulin resistance that begins early in its course. An additional complexity arises from the four-fold risk of Alzheimer’s Disease (AD) in type 2 diabetics, however there is no definitive proof of causation. Several strategies to improve brain insulin signaling have been proposed and some have been clinically tested. We report findings on a small allosteric molecule that reverses several indices of insulin insensitivity in both cell culture and in vitro models of AD that emphasize the intracellular accumulation of β-amyloid (Aβi). PS48, a chlorophenyl pentenoic acid, is an allosteric activator of PDK-1, which is an Akt-kinase in the insulin/PI3K pathway. PS48 was active at 10 nM to 1 μM in restoring normal insulin-dependent Akt activation and in mitigating Aβi peptide toxicity. Synaptic plasticity (LTP) in prefrontal cortical slices from normal rat exposed to Aβ oligomers also benefited from PS48. During these experiments, neither overstimulation of PI3K/Akt signaling nor toxic effects on cells was observed. Another neurotoxicity model producing insulin insensitivity, utilizing palmitic acid, also responded to PS48 treatment, thus validating the target and indicating that its therapeutic potential may extend outside of β-amyloid reliance. The described in vitro and cell based-in vitro coupled enzymatic assay systems proved suitable platforms to screen a preliminary library of new analogs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



![Fig 4 PS48 partly restores inhibited Akt phosphorylation (Akt activation) and GSK3β phosphorylation (Akt activity). In vitro additions of recombinant PDK (5 ng; 4A.) or pre-immunoprecipitated PDK-1 (4B.). 4A. Aβ peptide addition near completely results in Akt dephosphorylation (lane 3). PS48 added after Aβ peptide (post) in the reaction mixture completely reverses the loss of Akt phosphorylation (lane 5 vs. 3). When pre-added (pre), PS48 partially restores pAkt levels (lane 4). Note commercial recombinant Akt lots come variably phosphorylated (lane 1), but lack enzymatic activity in control reactions until PDK is added (see Figs 4B and 6B and text) and also undergo further phosphorylation. 4B. Restoration of Akt-catalyzed phosphorylation of GSK3β peptide (lanes 5 and 6 vs. 4). 4C. Quantified trend to reverse inhibited Akt activation and activity by PS48 in the presence of 10 μM Aβ42 oligomers (ADDLs). PS48 is active in the 10 nM range. Data from pAktT308, pAktS473 and pGSK3α/β S9 experiments were normalized and pooled (n = 3–6 ea.). ’Fraction of control Akt activation’ is the [Aβ (± PS48 presence) /Control] densitometry signals ratio, where 1.0 represents full restoration.* p < .02, t-test, Aβ 10μM/0μM PS48 (n = 6) vs. combined 100 nM and ≥ 1 μM (1, 10 and 100 μM) data (n = 8). The mean difference is 0.23 ± 0.08, 95% CI = [0.41 to 0.05].](https://figures.cochat.ai/paper-figures/b0063c3912814f66ab3f8479aaa0f08d/a-pdk-1-allosteric-agonist-neutralizes-insulin-signaling-derangements-and-beta-figure-4.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“For example, chlorphenylalic acid PS48 (57) targets PDK-1 allosteric pocket to restore Akt insulin responsiveness. The drug reduced Aβ toxicity without over-regulating insulin signaling, presenting a promising strategy for AD prevention or treatment.556”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [556]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Regulation of neuronal survival by the serine-threonine protein kinase Akt
Dudek, H., Datta, S. R., Franke, T. F., Birnbaum, M. J., Yao, R., Cooper, G. M., Segal, R. A., Kaplan, D. R., & Greenberg, M. E. (1997) · Science · doi:10.1126/science.275.5300.661 · Cited by 2,436
Diabetes mellitus and the risk of dementia: The Rotterdam Study
Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A. P., Hofman, A., & Breteler, M. M. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1937 · Cited by 2,175
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Bonni, A., Brunet, A., West, A. E., Datta, S. R., Takasu, M. A., & Greenberg, M. E. (1999) · Science · doi:10.1126/science.286.5443.1358 · Cited by 1,901
Talbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871 · cited 2×
“Lastly, IR in AD brain is linked to inhibitory feedback phosphorylations of IRS-1 (S616 and S636) by pS6K [27, 52].”
BackgroundDonanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728
Steen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Chen, Z., Liu, X., Zhu, Z., Chen, J., Wang, C., Chen, X., Zhu, S., & Zhang, A. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1039465 · Cited by 47
ARID1A mutation drives gastric tumorigenesis via activating type 2 immune dominant microenvironment
Arai, J., Hayakawa, Y., Suzuki, N., Kinoshita, H., Hata, M., Kurokawa, K., Matsushita, Y., Abe, S., Oya, Y., Tsuboi, M., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113117 · Cited by 11
Querfurth, H. W., Slitt, A. L., DiCamillo, A., Surles, N. O., DeBoef, B., & Lee, H. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4105279 · Cited by 8
Self-citationWu, J., Tang, J., Huang, D., Wang, Y., Zhou, E., Ru, Q., Xu, G., Chen, L., & Wu, Y. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1482947 · Cited by 8
Metadata
- Authors
- Querfurth, H., Marshall, J., Parang, K., Rioult-Pedotti, M. S., Tiwari, R., Kwon, B., Reisinger, S., & Lee, H.-K.
- Affiliations
- Tufts Medical Center (US)
- Brown University (US)
- Chapman University (US)
- University of Zurich (CH)
- Rhode Island Hospital (US)
- Corresponding author
- Querfurth, Henry
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2022-01-21
- Volume
- 17
- Issue
- 1
- Pages
- e0261696
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC8782417
- OpenAlex
- W4205278144
- Cited by
- 9
- References
- 172
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4 · 2022: 2
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Update notices
- correction (2024-05-29)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- The Brown Institute for Brain Science and Norman Prince Neuroscience Institute
- National Institute on Aging (AG044871-01)
- Bennett Foundation
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- PDK1, allosteric agonists, insulin resistance, Alzheimer's disease, amyloid-beta toxicity, PI3K/Akt signaling, synaptic plasticity, long-term potentiation, prefrontal cortex, palmitic acid, neuroprotection, drug screening
- MeSH terms
- Allosteric Regulation, Alzheimer Disease, Animals, Humans, Insulin, Neurons, Pentanoic Acids, Signal Transduction, Amyloid beta-Peptides, Rats, Sprague-Dawley, Cell Line, Tumor, Mice, Rats, 3-Phosphoinositide-Dependent Protein Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A PDK-1 allosteric agonist neutralizes insulin signaling derangements and beta-amyloid toxicity in neuronal cells and in vitro. https://app.cochat.ai/papers/10.1371/journal.pone.0261696
- The paper
- Querfurth, H., Marshall, J., Parang, K., Rioult-Pedotti, M. S., Tiwari, R., Kwon, B., Reisinger, S., & Lee, H.-K. (2022). A PDK-1 allosteric agonist neutralizes insulin signaling derangements and beta-amyloid toxicity in neuronal cells and in vitro. PLOS ONE. https://doi.org/10.1371/journal.pone.0261696
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.